Carmine SELLERI | Progetti

In this study, we aim at investigating the impact of ruxolitinib on marrow fibrosis in MPNs using a well-established 3D in vitro model of BM niche mimicking cell-to-cell contacts and paracrine pathways intercurrent between stromal cells and BMMCs in normal and pathological hematopoiesis.Specific aims: 1. Establishment of a 3D in vitro co-culture model of myelofibrosis.2. Ruxolitinib effects on

Based on findings showing the involvement of proinflammatory low-density granulocytes (LDGs) in activation of type 1 helper responses, and on the predominant role of cytotoxic T cells and type I immune responses in myelodysplastic syndromes (MDS), we hypothesize that LDGs and other immunoregulatory molecules might play an important role in MDS pathophysiology. Specific aims are to: 1) detect and q

The discovery of checkpoint inhibitors and engineered T cells has opened a new era in cancer immunotherapy and has changed clinical outcomes of several tumors. T cells expressing chimeric antigen receptors (CARs) are directed against specific tumor-related antigens. To date, only two CD19-specific CAR-T cells have been approved for B-cell acute lymphoblastic leukemia and diffuse large B cell lymph